Acetazolamide for Treatment Resistant Schizophrenia

Recruiting · NCT04887792 · Interventional (participants receive a specific treatment) · Lead sponsor: Vishwajit Nimgaonkar, MD PhD

Interventions studied

This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.

Age range

18 Years to 55 Years

Sex

All (male and female)

Healthy volunteers

No - a diagnosis or condition is required

Phase

Phase 1, Phase 2

Study type

Interventional (participants receive a specific treatment)

Written informed consent.
Both genders, ages 18-55 years (older patients may not tolerate high ACZ dose).
PANSS total score \> 60 and Score \> 4 on one or more items of the 'positive' syndrome items (P1-P7), following treatment at therapeutic doses for 6 weeks with different APDs on 2 occasions.
Stable dose of antipsychotic drug (APD) for \> 1 month, continued throughout the study.
Not participating in another randomized controlled clinical trial (RCT).

Substance abuse in the past month/dependence past 6 months with the exception of methadone prescribed for opiate withdrawal.
History or current medical/neurological illnesses that may lead to unstable course, e.g., epilepsy.
Pregnancy.
Acetazolamide (ACZ) contraindications: hypersensitivity to ACZ; history of renal hyperchloremic acidosis; Addison's disease/adrenal failure; chronic closed angle-closure glaucoma.
Current or prior treatment with ACZ or history of hypersensitivity to ACZ.
Intellectual disability as defined in DSM 5.

2 locations listed across 1 US state.